With no single headline event driving attention to IRADIMED (IRMD) today, investors are instead looking at the stock’s recent performance record and financial profile to reassess how it fits into a healthcare portfolio.

IRADIMED’s share price has been choppy in recent months, with the stock down around 7% over 90 days and 3% year to date, yet its 1 year total shareholder return of about 61% and 5 year total shareholder return above 250% still point to strong longer run momentum.

If IRADIMED’s track record has you thinking about where else growth could come from in healthcare technology, it may be worth scanning 40 healthcare AI stocks.

So, with IRADIMED now around $92 per share, solid revenue and net income figures, and a price target of $118, is the stock still trading below its fair value, or is the market already pricing in future growth?

Most Popular Narrative: 21.9% Undervalued

IRADIMED's most followed narrative pegs fair value at $118 per share, which sits well above the recent $92.20 close, and it leans heavily on product cycle and margin assumptions to get there.

The introduction and FDA approval of the new 3870 MRI compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers, unlocking large scale, recurring device and consumable revenues. This supports a step change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.

Want to see what sits behind that upgrade cycle story and the $118 fair value? The narrative refers to steady revenue gains, firm margins and a richer future earnings multiple, all pulled together using a 7.44% discount rate, but the exact mix of those inputs may surprise you.

Result: Fair Value of $118 (UNDERVALUED)

However, the IRADIMED story could look very different if its narrow MRI focused product range or any supply chain disruption slows pump shipments and revenue conversion.

Another View: What IRADIMED’s P/E Is Telling You

While the IRADIMED narrative leans on a fair value of $118, the current P/E of about 49.9x is high compared with both peers at 37.4x and a fair ratio of 19x. That gap points to clear valuation risk if sentiment cools or growth expectations reset.

To see how those earnings multiples stack up in more detail, including what the fair ratio suggests about where the market could move, take a look at the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

With sentiment clearly mixed around IRADIMED, now is the time to look at the numbers yourself and decide where you stand on the stock’s risk reward trade off. To frame that view with a structured breakdown of both potential upsides and areas of concern, take a look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond IRADIMED?

If IRADIMED has sharpened your focus on quality, do not stop here; broaden your watchlist with a few targeted stock ideas built from fundamental data.

• Capture potential mispricing by reviewing 45 high quality undervalued stocks that pair stronger fundamentals with prices that may not fully reflect their financial profile.
• Build staying power into your portfolio by checking out 65 resilient stocks with low risk scores that screen for sturdier balance sheets and calmer trading histories.
• Get ahead of the crowd by scanning the screener containing 19 high quality undiscovered gems that highlight solid businesses still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.